
Jagsonpal Pharmaceuticals Ltd is Rated Hold
2026-11-14 10:10:28Jagsonpal Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 8 November 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 November 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read MoreJagsonpal Pharmaceuticals Falls 1.41%: Mixed Technicals and Flat Financials Shape the Week
2026-11-08 16:01:06Key Events This Week 2 Nov: Technical momentum shifts amid mixed market signals 3 Nov: Downgrade to Sell rating amid flat financials and sideways technicals 5 Nov: Technical momentum shifts to mildly bullish despite mixed indicators 6 Nov: Week closes lower at ₹213.85 (-2.53%) Week OpenRs.216.90 Week Close<div class="...
Read More
Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-11-05 08:00:20Jagsonpal Pharmaceuticals Ltd has exhibited a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite this positive directional change, a detailed analysis of key technical indicators such as MACD, RSI, moving averages, and volume-based metrics reveals a complex picture that investors should carefully consider before making decisions.
Read MoreJagsonpal Pharmaceuticals Gains 2.46%: Technical Momentum and Financial Strength Drive Weekly Performance
2026-11-01 16:00:36Key Events This Week 26 Oct: Stock surged 5.53% to Rs.223.40 on upgrade to Hold rating 27 Oct: Technical momentum shifted to mildly bullish amid mixed indicator signals 29 Oct: Stock declined 3.51% on higher volume despite Sensex rally 30 Oct: Week closed at Rs.216.90, down 2.05% on the day but up 2.46% for the week Week OpenRs.211.70 <div class="...
Read More
Jagsonpal Pharmaceuticals Ltd Sees Technical Momentum Shift Amid Mixed Indicator Signals
2026-10-27 08:00:16Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend, supported by a combination of mixed signals from key technical indicators such as MACD, RSI, and moving averages. This development comes alongside a significant 5.53% gain in the stock price, reflecting renewed investor interest in the micro-cap pharmaceutical player.
Read MoreJagsonpal Pharmaceuticals Declines 3.33%: Technical Shifts and Valuation Concerns Shape Week
2026-10-25 16:00:36Key Events This Week 19 Oct: Downgrade to Sell rating by MarketsMOJO 21 Oct: Technical momentum shifts to sideways trend 23 Oct: Further technical deterioration to mildly bearish stance 23 Oct: Week closes at ₹211.70 (-3.33%) vs Sensex (-3.75%) Week Open₹219.00 Week Close₹211.70<div class...
Read More
Jagsonpal Pharmaceuticals Ltd Faces Technical Momentum Shift Amid Bearish Signals
2026-10-23 08:00:17Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, prompting a downgrade from Hold to Sell by MarketsMOJO on 19 Oct 2026. The micro-cap pharmaceutical firm’s share price has declined by 3.6% on the day, reflecting a broader mildly bearish trend across key technical indicators despite some longer-term bullish signals.
Read More
Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicators
2026-10-21 08:00:36Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish stance to a sideways trend. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, signalling a cautious outlook for investors amid mixed signals and a recent downgrade in its Mojo Grade to Sell.
Read More
Jagsonpal Pharmaceuticals Downgraded to Sell Amid Mixed Financials and Weak Technicals
2026-10-20 08:21:24Jagsonpal Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell as of 19 Oct 2026, reflecting a shift in technical indicators and valuation metrics despite recent positive quarterly financial results. The downgrade is driven by a combination of deteriorating technical trends, expensive valuation, modest long-term growth, and mixed financial performance, signalling caution for investors in this micro-cap pharmaceutical stock.
Read MoreAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript
03-Nov-2026 | Source : BSEEarning call transcript for Jagsonpal Pharmaceuticals Limited Q2 FY 27 Earning Conference Call on October 29 2026 at 2:00 P.M
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
29-Oct-2026 | Source : BSEAudio Recording of Jagsonpal Pharmaceuticals Limited Q2 FY27
Announcement under Regulation 30 (LODR)-Newspaper Publication
29-Oct-2026 | Source : BSENewspaper Publication providing extracts of Unaudited Results of Company for the quarter and half ended September 30 2026.
Corporate Actions
No Upcoming Board Meetings
Jagsonpal Pharmaceuticals Ltd has declared 200% dividend, ex-date: 04 Sep 26
Jagsonpal Pharmaceuticals Ltd has announced 2:5 stock split, ex-date: 08 Jan 25
No Bonus history available
No Rights history available